Non-invasive Helicobacter Pylori Testing Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Non-invasive helicobacter pylori testing market size was valued at around USD 273.6 million in 2023 and is estimated to grow at 7.1% CAGR from 2024 to 2032. The rising prevalence of gastric and duodenal illnesses, such as gastric cancer and peptic ulcer disease, is driving the demand for non-invasive Helicobacter Pylori (H. pylori) testing. H. pylori infection is a significant risk factor for these conditions, and non-invasive testing is often used as the first line of treatment for H. pylori infections.
According to data reported by American Cancer Society, approximately 26,890 new cases of stomach cancer are diagnosed each year in the U.S. including 16,160 cases in men and 10,730 cases in women. Furthermore, non-invasive methods are increasingly being used for the diagnosis of helicobacter pylori infections, particularly in children. High throughput diagnostic systems are being developed for local diagnostic testing, which can provide quick and accurate results.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Non-invasive Helicobacter Pylori Testing Market size in 2023: | USD 273.6 Million |
Forecast Period: | 2024 - 2032 |
Forecast Period 2023 - 2032 CAGR: | 7.1 |
2023 Value Projection: | USD 508.1 Million |
Historical Data for: | 2021 - 2023 |
No of Pages: | 105 |
Tables, Charts & Figures: | 118 |
Segments Covered: | Test Type, Method, End-use and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
Non-invasive helicobacter pylori testing refers to diagnostic methods used to detect the presence of H. pylori bacteria in the gastrointestinal tract without the need for invasive procedures such as endoscopy. These tests are designed to be simple, safe, and relatively comfortable for the patient, as they do not require the insertion of instruments into the body.
The latest advancements in laboratory serological assay for non-invasive Helicobacter pylori testing include the development of high throughput diagnostic systems for local diagnostic testing. These systems are designed to improve the efficiency and accuracy of helicobacter pylori testing.
Based on test type, the non-invasive H-pylori testing market is categorized into serologic test, urea breath test, and stool/fecal antigen test. The serologic test segment dominates the market with a revenue of around USD 110.7 million in 2023.
Based on method, the non-invasive helicobacter pylori testing market is categorized into laboratory-based test and point of care (POC) test. The laboratory-based test segment dominates the market with a revenue of around USD 170.2 million in 2023.
Based on end-use, the non-invasive helicobacter pylori testing market is categorized into hospitals, clinics, diagnostic laboratories, and other end users. The diagnostic labs segment held a majority market share with a revenue of around USD 119.5 million in 2023.
North America non-invasive helicobacter pylori testing market accounted for USD 97.7 million in revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
The U.S. held a dominant position in the North America non-invasive helicobacter pylori testing market, with a revenue of USD 90.2 million in 2023.
Japan non-invasive helicobacter pylori testing market is anticipated to witness substantial growth during 2024-2032.
China exhibits a high growth potential in the non-invasive helicobacter pylori testing market.
In Europe, the ongoing research and development efforts, fuels innovation in diagnostic technologies.
The non-invasive helicobacter pylori testing industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel diagnostic tests with improved efficiency and cost-effectiveness are key market strategies for industry players, driving competition and innovation in the market. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for advanced non-invasive H pylori testing.
Some of the eminent market participants operating in the non-invasive helicobacter pylori testing industry include:
Market, By Test Type
By Method
By End-user
The above information is provided for the following regions and countries:
Abbott, Biohit Oyj, Bio-Rad Laboratories, Inc., Cardinal Health, certest Biotech srl, Fisher Scientific, Gulf Coast Scientific, Meridian Bioscience Inc., Quidel Corporation, and Tri-Med, are some of the major non-invasive helicobacter pylori testing companies worldwide.
North America non-invasive helicobacter pylori testing industry reached USD 97.7 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to favorable reimbursement policies and the region's higher healthcare expenditure.
Non-invasive helicobacter pylori testing industry from the serologic test segment recorded USD 110.7 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to being convenient and preferable to patients.
Non-invasive helicobacter pylori testing market size was USD 273.6 million in 2023 and is expected to register 7.1% CAGR from 2024-2032 owing to the rising prevalence of gastric and duodenal illnesses, such as gastric cancer and peptic ulcer disease, worldwide.